AstraZeneca PLC (AZN)vsEquinor ASA ADR (EQNR)
AZN
AstraZeneca PLC
$181.86
-0.54%
HEALTHCARE · Cap: $283.47B
EQNR
Equinor ASA ADR
$36.69
-0.60%
ENERGY · Cap: $91.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 73% more annual revenue ($104.26B vs $60.44B). AZN leads profitability with a 17.2% profit margin vs 5.3%. EQNR appears more attractively valued with a PEG of 0.93. EQNR earns a higher WallStSmart Score of 65/100 (B-).
AZN
Buy62
out of 100
Grade: C+
EQNR
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.5%
Fair Value
$220.13
Current Price
$181.86
$38.27 discount
Margin of Safety
+46.5%
Fair Value
$53.41
Current Price
$36.69
$16.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Strong operational efficiency at 31.5%
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 29.2% YoY
Generating 2.1B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
5.3% margin — thin
Weak financial health signals
Revenue declined 5.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : EQNR
The strongest argument for EQNR centers on Operating Margin, Market Cap, PEG Ratio. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while EQNR is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.22 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
EQNR scores higher overall (65/100 vs 62/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?